Boston musings.
P2B or P3 may be the burning question.
Pathways??
I wonder if the new HIV/225 patents will be part of a change of tack, with regard to the parameters of the next trial. Will they pursue eradication or will they pursue to prove the human value of the immune response over a longer period.
Is a treatment interruption trial, as mentioned previously by MM in an interview, no longer a pipedream here?
Will they take aim at both?
How?
The Boston CROI connection, page-18
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.1¢ |
Change
-0.007(10.3%) |
Mkt cap ! $55.03M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.2¢ | 5.5¢ | $418.3K | 6.837M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 85063 | 6.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.3¢ | 14900 | 2 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
6.1¢ |
Change
-0.007 ( 10.3 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 5.6¢ | 1208244 | ||
| Last updated 15.44pm 26/04/2024 ? | |||||
| BIT (ASX) Chart |